ArticleResearch square2026
Integrative Proteomic Analysis Reveals VMG Oncolytic Virus-Induced Molecular Reprogramming in Pancreatic Ductal Adenocarcinoma.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival rate of 13.3%. This study investigates the treatment efficacy of VMG, a chimeric oncolytic vesiculovirus, against PDAC, focusing on its mechanism and therapeutic potential. VMG is engineered to replace the Vesicular Stomatitis Virus (VSV) glycoprotein (G) gene with the Morreton virus (MorV) glycoprotein, enhancing its safety, efficacy, and immune infiltration compared to wild-type VSV. We conducted an in-depth proteomic analysis of VMG treatment and evaluated its in vitro and in vivo efficacy. Our findings indicate that VMG treatment not only induces apoptosis and reduces tumor cell viability in PDAC cell lines, but also significantly slows tumor growth and enhances survival in PDAC mouse models. We then explored whether proteomic analysis could help uncover the mechanistic underpinnings of this efficacy. This approach allowed us to investigate the biological pathways involved in VMG's action. To understand these mechanisms, proteomic data were integrated with information from Ingenuity Pathway Analysis (IPA), the Kyoto Encyclopedia of Genes and Genomes (KEGG), and The Cancer Genome Atlas (TCGA). This analysis aimed to identify the key signaling pathways modulated by VMG. By integrating efficacy testing with proteomic and pathway analyses, we sought to clarify how VMG exerts its molecular effects. This approach offers a strong framework for uncovering the biological processes influenced by VMG. The study reveals that VMG treatment leads to a substantial overlap between virus-induced proteomic changes and prognostic markers found in the TCGA PDAC cohort. Specifically, VMG downregulates proteins associated with unfavorable prognosis, including those involved in altered mitochondrial function, genome DNA synthesis and repair, RNA modification, ribosome biogenesis, intracellular trafficking, cell cycle control, cytoskeletal dynamics, and palmitoylation. This multifaceted oncolytic mechanism disrupts fundamental processes driving PDAC progression, survival, and chemoresistance, providing a robust foundation for identifying novel therapeutic targets and biomarkers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.